Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

FFR - 6K: Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups

Company: Purple Biotech Ltd. Date: 2025-05-04 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.htm) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

   

6K: Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Sign false

|     |     |
| --- | --- |
| ���� ����� ��"� | 2 380 |
| PURPLE BIOTECH LTD |
| Corporation no: 520031238 | 12724 |
| - - - |
|     |

|     |     |     |     |     |     |     |     |     |     |     |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|     | Israel Securities Authority |     |     | Tel Aviv Stock Exchange |     | C002 ( Public ) |     | Reported via MAGNA: | 03/05/2025 |     |
|     | www.isa.gov.il |     |     | www.tase.co.il |     |     |     | Reference: | 2025-02-030733 | Time of broadcast: 22:03 22:03 |

- - -

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000  

  

|     |     |
| --- | --- |
|     | The corporation is a foreign private issuer as defined by U.S. Securities Laws. |

  

Attached hereto is a report on*6K: Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups*  

*ea023970304-6k\_purpleEDGAR2\_Bannerless\_isa.pdf*

|     |     |
| --- | --- |
|     |     |
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): |     |
|     |     |
|     |     |
| - - - |     |
| Stock Exchange/Market: NASDAQ CM | Date of revision of form structure: 06/08/2024 |
| Address: Oppenheimer, Science Park 4 , Rehovot 7670104   , Israel Tel: 03-9333121 , 03-9311321 Fax: 03-5097196 |     |
| E-mail address: ir@purple-biotech.com   Company site: www.kitovpharma.com |     |
|     |     |
| Previous names of reporting entity: KITOV PHARMA LTD, KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD, |     |
|     |     |
| Name of the Signatory: Masas Ludmer Adi Position of Signatory in the reporting corporation: Company Controller Name of Employer Company: |     |
| Address: Menachem Begin Drive 132 , Tel Aviv 6701101 Telephone: 03-9333121 Facsimile: 03-5097196 E-mail: adim@kitovpharma.com 1 |     |
| Israel |

Unlock Europe's Largest Financial Database—Free

Get instant access to over 2.8M filings from 8,970 companies across 44 markets. No cost. No hassle. Just results.

Save hours with instant data access
Trusted by leading financial institutions
Free forever—no strings attached

Or sign up with

Google Microsoft

Or log in with

Google Microsoft

This premium feature is designed for professionals. Upgrade your plan to gain immediate access and enhance your research capabilities.

Upgrade Now